Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer (Nature, (2015), 523, 7559, (177-182), 10.1038/nature14581);Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

Nature

Volumn 523, Issue 7559, 2015, Pages 177-182

  Melo, Sonia A ^a,e   Luecke, Linda B ^a   Kahlert, Christoph ^a   Fernandez, Agustin F ^b   Gammon, Seth T ^a   Kaye, Judith ^a   LeBleu, Valerie S ^a   Mittendorf, Elizabeth A ^a   Weitz, Juergen ^c   Rahbari, Nuh ^c   Reissfelder, Christoph ^c   Pilarsky, Christian ^c   Fraga, Mario F ^b,d   Piwnica Worms, David ^a   Kalluri, Raghu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; GLYPICAN 1; K RAS PROTEIN; MESSENGER RNA; BIOLOGICAL MARKER; GLYPICAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

CANCER; CELLS AND CELL COMPONENTS; DETECTION METHOD; ENDOCRINE SYSTEM; LIPID; MUTATION; NUCLEIC ACID; PROTEIN; RODENT; SECRETION; SERUM; SURVIVAL; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYSTADENOMA; EXOSOME; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID BILAYER; MAMMARY GLAND FAT; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREATITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR VOLUME; 3T3 CELL LINE; ANIMAL; BLOOD; DIAGNOSTIC USE; FEMALE; GENETICS; HCT116 CELL LINE; MALE; MCF 7 CELL LINE; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; EXOSOMES; FEMALE; GLYPICANS; HCT116 CELLS; HUMANS; MALE; MCF-7 CELLS; MICE; NIH 3T3 CELLS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84936980504     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-022-05062-9     Document Type: Erratum

References (50)

1. Pan, B. T., Teng, K., Wu, C., Adam, M. & Johnstone, R. M. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J. Cell Biol. 101, 942-948 (1985).
2. Trajkovic, K. et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244-1247 (2008).
3. Skog, J. et al. Glioblastomamicrovesicles transportRNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biol. 10, 1470-1476 (2008).
4. Al-Nedawi, K. et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature Cell Biol. 10, 619-624 (2008).
5. Demory Beckler, M. et al. Proteomic analysis of exosomes frommutantKRAScolon cancer cells identifies intercellular transfer of mutant KRAS. Mol. Cell Proteomics 12, 343-355 (2013).
6. Kahlert, C. et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J. Biol. Chem. 289, 3869-3875 (2014).
7. Ostrowski, M. et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nature Cell Biol. 12, 19-30 (2010).
8. Théry, C., Ostrowski, M. & Segura, E. Membrane vesicles as conveyors of immune responses. Nature Rev. Immunol. 9, 581-593 (2009).
9. Janowska-Wieczorek, A. et al.Microvesicles derivedfromactivated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 113, 752-760 (2005).
10. Hergenreider, E. et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nature Cell Biol. 14, 249-256 (2012).
11. Lotvall, J. et al. Minimal experimental requirements for definition of extracellular vesiclesandtheir functions: a positionstatement fromthe InternationalSociety for Extracellular Vesicles. J. Extracell. Vesicles 3, 26913 (2014).
12. Taylor, D. D. & Gercel-Taylor, C. Exosomes/microvesicles: mediators of cancerassociated immunosuppressive microenvironments. Semin. Immunopathol. 33, 441-454 (2011).
13. Luga, V. et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151, 1542-1556 (2012).
14. Théry, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. Chapter 3, Unit-3.22 (2006).
15. Théry, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. Nature Rev. Immunol. 2, 569-579 (2002).
16. Wilson, I. D. et al. High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J. Proteome Res. 4, 591-598 (2005).
17. Matsuda, K. et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 61, 5562-5569 (2001).
18. Kleeff, J. et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinomacells and is overexpressed in human pancreatic cancer. J. Clin. Invest. 102, 1662-1673 (1998).
19. Su, G. et al. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am. J. Pathol. 168, 2014-2026 (2006).
20. Kahlert, C. & Kalluri, R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med. 91, 431-437 (2013).
21. Morris, J. P., t., Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nature Rev. Cancer 10, 683-695 (2010).
22. Chen, W. W. et al. BEAMing and droplet digital PCR analysis ofmutant IDH1mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol. Ther. Nucleic Acids 2, e109 (2013).
23. Del Villano, B. C. et al. Radioimmunometric assay for a monoclonal antibodydefined tumor marker, CA 19-9. Clin. Chem. 29, 549-552 (1983).
24. Özdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719-734 (2014).
25. Ijichi, H. et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-b signaling in cooperation with active Kras expression. Genes Dev. 20, 3147-3160 (2006).
26. Lee, E. S. & Lee, J. M. Imaging diagnosis of pancreatic cancer: A state-of-the-art review. World J. Gastroenterol. 20, 7864-7877 (2014).
27. Rickes, S., Unkrodt, K., Neye, H., Ocran, K. W. & Wermke, W. Differentiation of pancreatic tumours by conventional ultrasound, unenhancedandecho-enhanced power Doppler sonography. Scand. J. Gastroenterol. 37, 1313-1320 (2002).
28. Murphy, S. J. et al. Genetic alterations associated with progression frompancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterol. 145, 1098-1109 (2013).
29. Bardeesy, N. & DePinho, R. A. Pancreatic cancer biology and genetics. Nature Rev. Cancer 2, 897-909 (2002).
30. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
31. Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617 (2010).
32. Ballehaninna, U. K. & Chamberlain, R. S. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 34, 3279-3292 (2013).
33. Jazieh, K. A., Foote,M.B.&Diaz, L.A. Jr. Theclinical utility ofbiomarkers inthemanagement of pancreatic adenocarcinoma. Semin. Radiat. Oncol. 24, 67-76 (2014).
34. Locker, G. Y. et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clinical Oncol. 24, 5313-5327 (2006).
35. Okano, K. & Suzuki, Y. Strategies for early detection of resectable pancreatic cancer. World J. Gastroenterol. 20, 11230-11240 (2014).
36. Conlon, K. C., Klimstra, D. S. & Brennan, M. F. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann. Surg. 223, 273-279 (1996).
37. Bilimoria, K. Y. et al. National failure to operate on early stage pancreatic cancer. Ann. Surg. 246, 173-180 (2007).
38. Murtaza,M. et al.Non-invasive analysis of acquiredresistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
39. Yong, E. Cancer biomarkers: Written in blood. Nature 511, 524-526 (2014).
40. David, G. et al. Molecular cloning of a phosphatidylinositol-anchored membrane heparan sulfate proteoglycan from human lung fibroblasts. J. Cell Biol. 111, 3165-3176 (1990).
41. Whipple, C. A., Young, A. L. & Korc,M. A KrasG12D-driven genetic mousemodel of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene 31, 2535-2544 (2012).
42. Aikawa, T. et al. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J. Clin. Invest. 118, 89-99 (2008).
43. Brand, R. E. et al. Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 17, 805-816 (2011).
44. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
45. Chen, H. & Boutros, P. C. VennDiagram: a package for the generation of highlycustomizable Venn and Euler diagrams in R. BMC Bioinformatics 12, 35 (2011).
46. Rachagani, S. et al. Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br. J. Cancer 104, 1038-1048 (2011).
47. Rothstein, D. M. et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J. Immunol. 166, 322-329 (2001).
48. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using realtime quantitative PCR and the 22DDC T method. Methods 25, 402-408 (2001).
49. Schmid, A., Braumuller, H., Wehrl, H. F., Rocken, M. & Pichler, B. J. Non-invasive monitoring of pancreatic tumor progression in the RIP1-Tag2mouse bymagnetic resonance imaging. Mol. Imaging Biol. 15, 186-193 (2013).
50. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two ormore correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837-845 (1988).